# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cannabis equity analysts may need to revise their 2024 earnings estimates after first-quarter results from major multi-state op...
In our January 2024 outlook, we asserted that cannabis equity analysts, having been burned by the need for continual downward r...
MariMed (OTC:MRMD) reported quarterly sales of $37.933 million which beat the analyst consensus estimate of $36.950 million by ...